The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Across 2026–2030?
The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market size has experienced robust expansion in recent years. It is projected to increase from $2.89 billion in 2025 to $3.1 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.3%. Historically, this growth was influenced by a restricted number of specialized peptide api manufacturers, the rising demand for peptide therapeutics, pharmaceutical companies’ reliance on in-house synthesis, necessary regulatory compliance, and a surge in preclinical and clinical trials.
The market size for peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing is set to demonstrate significant expansion over the forthcoming years. It is projected to achieve a value of $4.11 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.3%. This anticipated growth throughout the forecast period stems from factors such as the broadening of CMO capabilities for peptide API, escalating investments in advanced peptide synthesis technologies, the rise of personalized medicine and biologics, increased outsourcing by smaller and medium-sized pharmaceutical enterprises, and the implementation of digital manufacturing paired with AI-based process optimization. Key developments during this period are expected to feature a heightened demand for contract manufacturing of peptide APIs, a greater emphasis on GMP-grade production and adherence to regulations, an expansion in outsourced peptide synthesis for clinical trials, the proliferation of process optimization and tech transfer services, and the embracing of custom peptide synthesis for personalized treatments.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25870&type=smp
Which Market Drivers Are Supporting The Expansion Of The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?
An increasing occurrence of diabetes is projected to fuel the expansion of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in the future. Diabetes is characterized as a chronic metabolic condition defined by high blood glucose levels, which results from the body’s inadequate insulin production or its impaired ability to utilize insulin efficiently. The expanding incidence of diabetes is largely driven by rising obesity rates, given that excessive body fat contributes to insulin resistance and interferes with blood sugar regulation. Peptide therapeutics utilize contract API manufacturing to facilitate the mass production of hormone-mimicking medications, thereby improving insulin secretion and glucose management in treating diabetes. For example, in March 2025, a report from the Office for Health Improvement and Disparities, a UK-based government department, indicated that the documented prevalence of type 2 diabetes among adults aged 17 and over in England reached 7.0% by March 2024, an increase from 6.8% in March 2023. Consequently, the increasing prevalence of diabetes is accelerating the growth of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market.
What Segmentation Levels Are Considered In The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?
The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market covered in this report is segmented –
1) By Scale Of Operation: Preclinical Or Clinical, Commercial
2) By Synthesis Method: Non Chemical Synthesis, Chemical Synthesis
3) By Enterprise Type: Large Enterprise, Small And Medium Enterprises
Subsegments:
1) By Preclinical Or Clinical: Discovery And Preclinical Development, Phase II Or III Manufacturing, Phase I Manufacturing
2) By Commercial: Commercial-Scale Good Manufacturing Practice Manufacturing, Tech Transfer And Scale-up, Lifecycle Management Or Process Optimization
What Trends Are Projected To Affect The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?
Leading companies in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market are prioritizing the development of innovative solutions, such as the continuous flow synthesis platform, to streamline production and tackle the rising complexity in drug development. This continuous flow synthesis platform integrates multiple stages, including reaction, separation, concentration, and crystallization, into one unbroken process with real-time in-line measurement, enabling high-precision, non-destructive monitoring and efficient scale-up. For instance, in May 2023, SynCrest Inc., a Japan-based contract research, development, and manufacturing organization (CRDMO), announced the launch of its good manufacturing practice (GMP)-compliant Naruto Plant, equipped with a continuous flow synthesis platform for peptide and nucleotide API production. The platform allows for the rapid and high-quality manufacturing of over 100 types of non-natural amino acids and high-purity special amidites, significantly decreasing both lead times and production costs. This innovation is addressing the expanding market demand for advanced peptide-based therapeutics by offering scalable, efficient, and cost-effective API manufacturing solutions.
Which Leading Firms Are Contributing To The Growth Of The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?
Major companies operating in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market are Thermo Fisher Scientific Inc., Lonza Group AG., WuXi AppTec Co. Ltd., Cambrex Corporation, ChemPartner, GenScript Biotech Corporation, Bachem Group, CordenPharma International GmbH, Syngene International Limited, Ambiopharm Inc., CPC Scientific Inc., ScinoPharm Taiwan Ltd., Hybio Pharmaceutical Co. Ltd., CSBio Company Inc., Senn Chemicals AG., AnaSpec Inc., LifeTein LLC, Apex Biotechnology Corp., BCN Peptides S.A.
Read the full peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market report here:
How Is The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Distributed Across Key Geographic Regions?
North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25870&type=smp
Browse Through More Reports Similar to the Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market 2026, By The Business Research Company
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Peptide Synthesis Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-synthesis-global-market-report
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model